Situgen Med News
2 articles
growth-positive
SituGen Ltd. Completes Clinical Trials of Revolutionary Device for Umbilical Cord Blood Collection BioSpace
SituGen Ltd. has announced the completion of clinical trials for its innovative device for collecting umbilical cord blood. The trials showed that the device increased the number of stem cells collected by 81%, significantly improving the quantity and quality of stem cells available for transplantation. FDA approval is expected later this year, with European approval to follow. SituGen plans to manufacture and market the device to cord blood banks worldwide. The company also intends to continue research and development in the stem cell and cord blood fields. SituGen was founded in 2003 and is supported by RAD BioMed as an investor and partner.
CustomersPartners
growth-positive
Israeli device lengthens the stem cell cord that save lives
Israeli start-up BioCord has developed the SituGen system, a novel method for collecting more stem cells from the umbilical cord. The current method of extracting cord blood using a needle limits the amount of blood that can be collected. The SituGen system, which does away with the needle, can collect more than double the amount of blood, allowing for the treatment of more illnesses and potentially saving more lives. BioCord is raising $500,000 in funding to market and produce the SituGen system, in addition to the $500,000 already invested by private investors and the Israeli Chief Scientist. The device will cost around $100 and will be distributed through multinational companies to cord blood banks worldwide.
Customers
